News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

New trial: Cellular Immunotherapy with Alloreactive CTL for Recurrent WHO Grade III Gliomas - at UCLA


Posted on: 03/16/2012

New trial: Cellular Immunotherapy with Alloreactive CTL

An Open Study at UCLA Medical Center

for Recurrent WHO Grade III Gliomas 

Click HERE for details.  (A .pdf will open in new window)

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740